Danka Radosavljevic - 31 Jul 2026 Form 3 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Reporting relationship
Chief Operating Officer
Issuer ticker
ETON
Reported as of
31 Jul 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
12 Aug 2026, 17:00:44 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Judith Matthews

Key filing fact

Danka Radosavljevic filed Form 3 for Eton Pharmaceuticals, Inc. (ETON) on 12 Aug 2026.

Key facts

  • This page summarizes Danka Radosavljevic's Form 3 filing for Eton Pharmaceuticals, Inc. (ETON).
  • 0 reported transactions and 12 derivative rows are listed below.
  • Accepted by SEC: 12 Aug 2026, 17:00.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002149737 Primary reporting owner

Radosavljevic Danka

Relationship
Chief Operating Officer
Address
C/ ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK
Signature
/s/ Judith Matthews
Signature date
12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ETON holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
22,473
Date
31 Jul 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ETON holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
31,508
Exercise price
$15.47
Footnotes
F1
ETON holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,039
Exercise price
$0.000000
Footnotes
F2, F3
ETON holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,194
Exercise price
$0.000000
Footnotes
F3, F4
ETON holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
14,317
Exercise price
$13.00
Footnotes
F5
ETON holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,000
Exercise price
$14.68
Footnotes
F6
ETON holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
92,993
Exercise price
$4.42
Footnotes
F7
ETON holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,000
Exercise price
$4.74
Footnotes
F8
ETON holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
42,224
Exercise price
$3.47
Footnotes
F9
ETON holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
35,000
Exercise price
$8.61
Footnotes
F10
ETON holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
60,000
Exercise price
$3.58
Footnotes
F11
ETON holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
18,742
Exercise price
$1.38
Footnotes
F12
ETON holding Derivative

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
128,985
Exercise price
$0.000000
Footnotes
F13
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 13 footnotes

Footnote F1

The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030.

Footnote F2

The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.

Footnote F4

The restricted stock units vest in four equal annual installments beginning January 3, 2026, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

Footnote F5

The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 3, 2029.

Footnote F6

The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on March 18, 2029.

Footnote F7

The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 13, 2028.

Footnote F8

The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on August 15, 2027.

Footnote F9

The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 20, 2027.

Footnote F10

The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on May 3, 2025.

Footnote F11

The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on March 12, 2024.

Footnote F12

The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on July 24, 2021.

Footnote F13

On July 31, 2026, the reporting person was granted 128,985 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029. The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.

SEC remarks

The reporting person has authorized and designated the named person to file this Form 3 on the reporting person's behalf for indefinite duration.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .